News from REMEDY

Kristine Røren Nordén has researched how personalized, high-intensity training can improve aerobic capacity in these patients. 

Diseases that are part of the specialty of rheumatology are often referred to as rheumatic diseases or rheumatological diseases. Among rheumatologists, there are divided opinions about which of these terms is preferred, and this is the topic of the language column in the journal 25.10.24

The hospital is in the process of completing a state-of-the-art biobank facility at Vinderen. The facility will ensure the safe storage of valuable biological material. This is important for the hospital's long-term focus on research and personalized medicine. The facilities will be ready by the end of 2024.

Minister of Health Jan Christian Vestre visited Diakonhjemmet Hospital on October 15. He wants to ensure that the apps in work package 5 do not have to be CE marked as high-risk medical devices.

The All About Clinical Trials course will be held at Diakonhjemmet Hospital, Oslo, 12-13 December 2024.  It is a generic course that covers all aspects of clinical trials. Although it is built by cardiologists, it is relevant to anyone interested in clinical trials. The course is particularly well suited for PhD candidates. 

New research project on biological medicines:

“This will be a national boost. We hope that we will conduct a study that can change clinical practice,” says project manager Silje Watterdal Syversen at the REMEDY Center.

Ingvild Kjeken speaks in this webinar about patient education and lifestyle changes, based on insights that emerged from this year's EULAR conference in Vienna, in June 2024. 

Cand. Med. Ingrid Egeland Christensen has recently completed her doctorate at Diakonhjemmet Hospital and the research center REMEDY. Her thesis, Serious infections in patients with inflammatory joint diseases, highlights the increased risk of serious infections in patients treated with biological drugs.

In the second quarter of this year, we have received 37 media reports. Here is a little more information about some of them. The overview of those found is in the table at the bottom of this issue. You will also find links to the cases that it was possible to link to. 

Don't miss this year's hashtag#MUSS, the national research conference for musculoskeletal health!

Today, all patients with rheumatoid arthritis receive the same dose of biologic drugs. Now, researchers are investigating whether individually tailored doses will allow more people to benefit from the medications.